Business Context and Reporting Period
MIRA Pharmaceuticals, Inc. (MIRA), an emerging growth company incorporated in Florida, filed this Form 8-K on July 3, 2025. The filing reports a specific equity financing event executed on the same date.
Key Financial Metrics
This filing details a capital raise rather than periodic operating results. Key transaction metrics include:
- Shares Sold: 1,550,741 shares of common stock.
- Average Price: $1.2981 per share.
- Gross Proceeds: Approximately $2.0 million (prior to fees and expenses).
- Pricing Context: The sale price represented a premium to the prior day's closing price.
- Facility Used: At-the-market equity offering facility.
- Facilitator: Rodman & Renshaw via the StockBlock platform.
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change is the increase in outstanding common stock and the infusion of gross proceeds of approximately $2.0 million. The transaction was executed as a block sale to an institutional investor and did not include any warrants.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the equity sale. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the net proceeds after deducting fees and expenses from the $2.0 million gross amount.
- Confirm the updated total number of outstanding shares post-transaction.
- Review the Company's most recent 10-Q or 10-K for current cash balances and burn rate to assess the impact of the $2.0 million raise on liquidity.
- Check for any subsequent filings regarding the use of proceeds or additional sales under the at-the-market facility.